Efamol claimed that two of its products could treat ADHD symptoms in children by managing fatty acid deficiencies. The FTC filed a complaint alleging that reliable scientific evidence did not exist that supported such a claim, in violation of the Federal Trade Commission Act. Efamol agreed to cease advertising that its products were effective at treating ADHD unless it could produce competent and reliable evidence that supported the company’s claim. In exchange for the voluntary cessation of the subject advertising, the FTC agreed to withdraw its complaint.
The full case and consent order is also available at: http://www.mlmlegal.com/legal-cases/IntheMatterofEfamolNutraceuticalsInc.php
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Published In:
MLM / Direct Sales Updates, MLM Consulting / Network Marketing Updates
Reference Info:
Federal, Federal Circuit |
United States
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Babener & Associates | Attorney Advertising
